Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

IDENTIFIER (ClinicalTrials.gov):  NCT06041516

DRUG/TREATMENT: ADCT-701 is given through a tube attached to a needle inserted into a vein in the arm.

PHASE: First-in-Human Phase I Trial

STATUS: Recruiting

SPONSOR: National Cancer Institute (NCI)

DESCRIPTION:

This is a first in human phase 1 study to test a new drug, ADCT-701, in people with Neuroendocrine neoplasms (NENs). 

ADCT-701 is an antibody drug conjugate (or ADC) that specifically targets "Delta Like Non-Canonical Notch Ligand 1" or DLK1, an antigen which has recently been found to be expressed on neuroendocrine cancers. The hope is this drug will  suppress tumor growth, shrink tumors after tumor growth, and improve survival. 

*Note: This study includes all neuroendocrine neoplasms including neuroendocrine tumors, neuroendocrine carcinomas (i.e. "high grade neuroendocrine cancers"), pheochromocytoma, paraganglioma and adrenocortical carcinoma (ACC). 

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

National Cancer Institute Medical Oncology

Kimberley J Cooper

EMAIL: kimberley.cooper@nih.gov

PHONE: 240-858-5798

Principal investigator: Jaydira Del Rivero, M.D.,National Cancer Institute (NCI)

LOCATIONS:

National Instititues of Health Clinical Center: Bethesda, Maryland, United States 20892